Chromatin

Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
星期二, 四月 23, 2024
Ballroom, Safety, Transgene, Express, Lipid, Monocyte, Chromatin, Research fellow, IPS, MD, Cell, Gene targeting, Development, Macrophage, DNA, Gene, Society, Messenger, Annual general meeting, Dicarboxylic acid, Vaccine

CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting to be held in Baltimore, MD from May 7-11, 2024. Factor will deliver seven presentations, representing the company's most expansive presentation of data to date.

Key Points: 
  • CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting to be held in Baltimore, MD from May 7-11, 2024.
  • Factor will deliver seven presentations, representing the company's most expansive presentation of data to date.
  • "Factor will deliver seven presentations, representing the company's most expansive presentation of data to date."
  • For more information about the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, visit annualmeeting.asgct.org .

Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024

Retrieved on: 
星期三, 四月 10, 2024
DNA replication, PARP1, Olaparib, PARG, CRISPR, PARP, HR, IC50, ADME, DNA, Chromatin, PDD, San Diego Convention Center, FEN1, DNA repair, DDR, EC50, Blacksmith, Niraparib, Erosion (morphology), AACR, ATR, Drug discovery, USP1, SAN, Pharmaceutical industry

"Using our metalloenzyme fragment-based drug discovery approach, we have identified a highly potent and selective inhibitor of FEN1 having synergies with multiple DDR drug classes that include inhibitors of PARP, PARG, USP1, and ATR."

Key Points: 
  • "Using our metalloenzyme fragment-based drug discovery approach, we have identified a highly potent and selective inhibitor of FEN1 having synergies with multiple DDR drug classes that include inhibitors of PARP, PARG, USP1, and ATR."
  • The Blacksmith fragment-based drug discovery platform identified a novel metal-binding pharmacophore that binds to the two magnesium ions in the FEN1 active site.
  • Further elaboration using fragment growth strategies resulted in highly potent and selective inhibitors.
  • Title: "Small molecule inhibitor of FEN1 nuclease utilizing a novel metal binding pharmacophore synergizes with inhibitors of USP1, PARP, PARG and ATR"

Dovetail Genomics Introduces Novel LinkPrep™ NGS Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
星期二, 四月 9, 2024
Genetic variation, Gene, Genetics, Patient, NGS, 3D, Chromatin, Cancer, Genome, Workflow, Genomics, Poster, Chromosomal translocation, Mobile phone

BOSTON, April 9, 2024 /PRNewswire/ -- Dovetail Genomics today announces the debut of its LinkPrep™ NGS technology, showcasing its potential for de novo detection of structural variants and chromatin topology features in cancer. Through its innovative chromatin conformation approach, LinkPrep™ technology exhibits enhanced sensitivity in detecting translocations and intra-chromosomal rearrangements compared to conventional methods, while also identifying SNVs/InDels within a single assay. Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift. These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.

Key Points: 
  • Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift.
  • These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.
  • This will improve the discovery and annotation of novel drivers and mechanisms of cancer.
  • Currently undergoing late-stage validation, Dovetail Genomics is actively seeking strategic partnerships to conduct further studies demonstrating its clinical utility across specific cancer indications.

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

Retrieved on: 
星期四, 三月 21, 2024
Cancer, Principal, Enzyme, DNA repair, Biochemistry, Survival, Professor, Monroe Dunaway Anderson, Patient, Neoplasm, DNA, History, Breast, Prostate, Protein, University, MD Anderson Cancer Center, PARP, Therapy, ALC1, Chromatin, CSO, LP, Pharmaceutical industry

EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.

Key Points: 
  • EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.
  • By hindering DNA repair, PARP inhibitors cause tumor cell death, and they have been effective therapies for many ovarian, breast, prostate, and pancreatic cancers.
  • EIS-12656 inhibits the chromatin remodeling enzyme ALC1, which is critical to the DNA repair process associated with PARP activation.
  • EIS-12656 was developed by Eisbach to disrupt DNA-damage-dependent PARP activation at an early stage of the repair process.

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Retrieved on: 
星期四, 三月 7, 2024
EP300, NSCLC, Merck, Research, AML, Neoplasm, ARID1B, Investment, CBP, Cancer, Prostate, AACR, Factorization of polynomials, Lung cancer, Safety, MDS, Collaboration, Gene expression, Thrombocytopenia, Lilly, Medicine, Patient, Survival, IND, LDAC, Development, Colorectal cancer, BRM, Chromatin, Prostate cancer, Pharmaceutical industry

“In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.

Key Points: 
  • “In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.
  • The IND is planned for the second quarter of 2024, with an initial focus in non-small cell lung cancer.
  • The Company is conducting preclinical work to further explore the opportunity and expects data in the second quarter of 2024.
  • Foghorn is presenting new preclinical data for its CBP and EP300 selective degrader programs at the 2024 AACR Annual Meeting, April 5-10, 2024.

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

Retrieved on: 
星期二, 三月 5, 2024
EP300, PD, Chemistry, CBP, BRD9, Chromatin, AACR, SMARCA2, Safety, Gene expression, Thrombocytopenia, Lilly, IND, Poster, BRM, Pharmaceutical industry

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that preclinical data for its pipeline programs, including the first presentation of preclinical data for FHD-909, a potential first-in-class BRM (SMARCA2) selective inhibitor will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California. In addition to the FHD-909 poster, the Company will have a symposium presentation, a town hall talk, and poster presentations on its selective CBP degrader and selective EP300 degrader programs.

Key Points: 
  • In addition to the FHD-909 poster, the Company will have a symposium presentation, a town hall talk, and poster presentations on its selective CBP degrader and selective EP300 degrader programs.
  • “Our 2024 AACR presentations showcase the significant progress that Foghorn has made advancing multiple potential first-in-class medicines, based on our unique capabilities targeting the chromatin regulatory system” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn.
  • In addition, we will present data highlighting our long-acting formulation capabilities that enable up to once-a-month dosing for protein degraders, which we believe meaningfully differentiate our programs and platform.”
    Symposium Session: TM04 – Losing our inhibitions – is (protein) degradation preferred?
  • : A chemistry in Cancer Research Working Group Town Hall Meeting
    Poster Title: Identification of selective CBP degraders with robust preclinical PK, PD, efficacy and safety across solid tumor indications
    Poster Title: Long acting injectable FHD-609 micro-suspension: A potent BRD9 degrader with comparable efficacy, reduced frequency of dosing in preclinical models
    The presentation and the posters will be accessible under the Science section of the Company’s website after the conference.

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Retrieved on: 
星期二, 三月 5, 2024
NSCLC, BTK, CRC, AACR, SMARCA2, BCL2, Breast, Breast cancer, Webcast, Science, CDK9, Chromatin, Pharmaceutical industry

WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place from April 5 to 10, 2024.

Key Points: 
  • WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place from April 5 to 10, 2024.
  • Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude, stated, “We look forward to sharing data on the preclinical characterization of our lead oral SMARCA2 degrader, PRT7732, which is on track to advance into Phase 1 clinical development in the second half of this year, and to presenting additional preclinical data for our highly selective and potent CDK9 inhibitor, PRT2527, that supports its potential therapeutic value in combination with BTK and BCL2 inhibitors in lymphoid malignancies.
  • To attend in person or via webcast, visit: https://edge.media-server.com/mmc/p/5dwkjbcy .
  • A replay of the webcast will be available on the Prelude website for 90 days.

UT Health San Antonio secures $16.4 million from CPRIT over six months, adding transformative expertise, bolstering cancer research

Retrieved on: 
星期五, 三月 8, 2024
Doctor of Philosophy, Education, MD, Drug development, DNA repair, National Cancer Institute, Breast, University, RNA, Research institute, Ovarian cancer, Cell Systems, Health, Genetics, Anatomy, Biochemistry, Bangladesh Technical Education Board, Algorithm, Adolescence, Nursing, Neoplasm, Kitagawa, Faculty, Dentistry, HPV, Child, DNA, Chromatin, Therapy, SAN, National Institutes of Health, Mentorship, Chromosome instability, Doctor of Pharmacy, Structural biology, Vaccination, Cancer Research Institute, Molecular medicine, News, Laboratory, Research, University of Texas System, Cedars-Sinai Medical Center, Survivor, BRCA2, Cell, Howard Hughes Medical Institute, School, Cancer prevention, Luan, BRCA1, Patient, Teaching, Ewing sarcoma, Cancer, Public, Vaccine

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) (https://uthscsa.edu/) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas (https://www.cprit.state.tx.us/about-us) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.

Key Points: 
  • SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ( https://uthscsa.edu/ ) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas ( https://www.cprit.state.tx.us/about-us ) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.
  • The Mays Cancer Center at UT Health San Antonio ( https://cancer.uthscsa.edu/ ) is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.
  • The Greehey Children's Cancer Research Institute ( https://cancer.uthscsa.edu/gccri ) is one of only two institutes in the United States dedicated solely to pediatric cancer research.

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
星期五, 二月 16, 2024
Nucleosome, ATAC, Kanazawa University, CRISPR, Gene editing, Stem cell, B cell, TFDP1, Genome, Digital selective calling, Protein, Gene, Histone, DNA, Running, Chromatin, Vaccine

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

Retrieved on: 
星期五, 二月 16, 2024
Nucleosome, ATAC, Kanazawa University, CRISPR, Gene editing, Stem cell, B cell, TFDP1, Genome, Digital selective calling, Protein, Gene, Histone, DNA, Running, Chromatin, Vaccine

KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.

Key Points: 
  • KANAZAWA, Japan, Feb. 16, 2024 /PRNewswire/ -- In a study recently published in Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access pathways to the genomic DNA, and its use as a tool for gene editing.
  • This phenomenon known as 'chromatin accessibility' involves a privileged set of protein molecules, many of which are still unknown.
  • Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways.
  • In this study the genes identified by CRISPR screening were subjected to ATAC-see to confirm their involvement with chromatin accessibility.